Shares of Evotec SE (NASDAQ:EVO - Get Free Report) saw unusually-high trading volume on Friday . Approximately 100,459 shares traded hands during mid-day trading, a decline of 5% from the previous session's volume of 106,043 shares.The stock last traded at $3.89 and had previously closed at $3.87.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on EVO shares. Jefferies Financial Group downgraded Evotec from a "buy" rating to a "hold" rating and cut their price target for the stock from $8.70 to $3.80 in a research note on Monday, October 7th. HC Wainwright cut their target price on shares of Evotec from $11.00 to $8.00 and set a "buy" rating on the stock in a report on Thursday, August 15th. Morgan Stanley cut shares of Evotec from an "overweight" rating to an "equal weight" rating and dropped their target price for the stock from $15.00 to $6.00 in a research report on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Evotec from a "hold" rating to a "sell" rating in a research note on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $5.93.
View Our Latest Stock Analysis on Evotec
Evotec Stock Up 0.3 %
The business's 50 day simple moving average is $3.45 and its two-hundred day simple moving average is $4.36. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.73 and a current ratio of 1.83.
Hedge Funds Weigh In On Evotec
Several institutional investors have recently made changes to their positions in the business. Vanguard Personalized Indexing Management LLC purchased a new stake in Evotec in the 2nd quarter worth approximately $87,000. Clear Harbor Asset Management LLC purchased a new stake in shares of Evotec in the third quarter worth $104,000. Cetera Advisors LLC bought a new stake in shares of Evotec during the 1st quarter valued at $188,000. Mediolanum International Funds Ltd purchased a new position in shares of Evotec in the third quarter valued at about $512,000. Finally, DCF Advisers LLC lifted its holdings in Evotec by 140.5% in the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock worth $552,000 after purchasing an additional 67,156 shares in the last quarter. Institutional investors own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
